<DOC>
	<DOCNO>NCT01607294</DOCNO>
	<brief_summary>This Phase 2 study ass LDL-C lower efficacy ETC-1002 versus placebo subject type 2 diabetes .</brief_summary>
	<brief_title>A Single Center Study Evaluate Efficacy Safety ETC 1002 Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Diagnosis type 2 diabetes meet follow : Minimum 6 month history diabetes prior screening visit ; Fasting Cpeptide ≥ 0.8 ng/mL screen visit ; HbA1C screen visit 710 % ; Fasting glucose 140270 mg/dL Day 7 follow washout glucose regulate drug supplement . BMI screen visit 2535 kg/m2 ; LDLC screen ≥ 100 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>